Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. (RANI) priced its initial public offering on Aug 2, 2021 at $11.00 per share, below its $14.00–$16.00 range, raising $73.3M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $528.1M. BofA Securities was lead-left underwriter, joined by Stifel, Cantor and Canaccord Genuity and others. Cooley advised the company and Goodwin Procter advised the underwriters.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing technology for orally administered biologics. Its RaniPill capsule is an ingestible pill intended to replace subcutaneous or IV injection by automatically delivering a precise therapeutic dose.

Status

IPO

Ticker

RANI

Exchange

Nasdaq Global Market

Priced

Aug 2, 2021

IPO price

$11.00

Price range

$14.00–$16.00

Raised

$73.3M

Market cap at IPO price

$528.1M

First filed

Jul 9, 2021

Underwriters

BofA Securities, Stifel, Cantor, Canaccord Genuity and BTIG

Company counsel

Cooley

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.